Gene Mack - 20 Mar 2025 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role
CEO, President, Director
Signature
/s/ Gene Mack
Issuer symbol
GANX
Transactions as of
20 Mar 2025
Net transactions value
$0
Form type
4
Filing time
21 Mar 2025, 20:00:04 UTC
Previous filing
07 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GANX Employee Stock Option (right to buy) Award $0 +200,000 $0.000000 200,000 20 Mar 2025 Common Stock 200,000 $2.29 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option shall vest as to 25% on March 20, 2026, and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.